EGFR and lung adenocarcinoma: The clinical utility of using a single gene-based biomarker as a therapeutic focus for lung adenocarcinoma was first realized with the discovery of mutations in the tyrosine kinase domain of EGFR in 2004; this enabled the identification of patients with greater sensitivity to TKIs (38, 44).